9BNF
SARS-CoV-2 spike HexaPro protein in complex with T5A trimeric antagonist
Summary for 9BNF
| Entry DOI | 10.2210/pdb9bnf/pdb |
| EMDB information | 44726 |
| Descriptor | Collagen alpha-1(XVIII) chain,Processed angiotensin-converting enzyme 2, Spike glycoprotein, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, ... (4 entities in total) |
| Functional Keywords | trimeric antagonist sars-cov-2 complex, viral protein-antagonist complex, viral protein/antagonist |
| Biological source | Homo sapiens (human) More |
| Total number of polymer chains | 6 |
| Total formula weight | 676059.43 |
| Authors | Young, T. (deposition date: 2024-05-02, release date: 2025-08-27, Last modification date: 2025-10-29) |
| Primary citation | Gonzales, J.,Young, T.,Choi, H.,Park, M.,Jewel, Y.,Fan, C.,Purohit, R.,Bjorkman, P.J.,Williams, J.C. Development of an ultrahigh affinity, trimeric ACE2 biologic as a universal SARS-CoV-2 antagonist. Commun Biol, 8:1428-1428, 2025 Cited by PubMed Abstract: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), responsible for the COVID-19 pandemic, utilizes membrane-bound, angiotensin-converting enzyme II (ACE2) for internalization and infection. We describe the development of a biologic that takes advantage of the proximity of the N-terminus of bound ACE2 to the three-fold symmetry axis of the spike protein to create an ultrapotent, trivalent ACE2 entry antagonist. Distinct disulfide bonds were added to enhance serum stability and a single point mutation was introduced to eliminate enzymatic activity. Through surface plasmon resonance, pseudovirus neutralization assays, and single-particle cryo-electron microscopy, we show this antagonist binds to and inhibits SARS-CoV-2 variants. We further show the antagonist binds to and inhibits a 2003 SARS-CoV-1 strain. Collectively, structural insight has allowed us to design a universal trivalent antagonist against all variants of SARS-CoV-2 tested, suggesting it will be active against the emergence of future mutants. PubMed: 41053501DOI: 10.1038/s42003-025-08819-w PDB entries with the same primary citation |
| Experimental method | ELECTRON MICROSCOPY (3.33 Å) |
Structure validation
Download full validation report






